Dr. Scott Liu, President and CEO of Shanghai Henlius Biotech Inc., has a Ph.D. degree in biology from Purdue University.  He also had a postdoctoral training in biology at Stanford University, and later studied business administration (iMBA courses) at Syracuse University.  Dr. Liu has many years of experience in management and leadership.  He has previously served as a VP of R&D of United Biomedical, the fouding director of the Biologics QC department of Bristol-Myers Squibb-Syracuse, and the QAL (QC) director of Amgen-Fremont.  Dr. Liu was a key member of the CMC teams for the late-phase development and commercial cGMP manufacturing of Orencia and Vectibix.  Because of his outstanding achievement, Dr. Liu has won the Bristol-Myers Squibb Company's Tech Ops President Award.  Liu Scott has 21 years of experience in biopharmaceutical R&D, regulatory affairs and quality operations, and he was awarded the title of "1000 Expert of Shanghai" in 2013.  At the same time, Dr. Liu assisted the formation of“Quality Alliance of Protein Therapeutics”and helped the CDE of CFDA in the establishment and improvement of the quality standards for protein therapeutics in China.  He also took the lead to promote an industry-wide adoption of single-use technologies into clinical and commercialization of manufacturing of monoclonal antibody drugs; and actively participated in the development of 《Technical Guidelines of Biosimilar Development and Evaluation》to promote the innovation and globalization of the biopharmaceutical industry of China.  Under his leadership, Henlius has successfully developed and moved into clinical trials six mAb therapeutics (including one innovative mAb), and the first two of which are in phase 3 trials.  Henlius has also successfully built a commercial biologics manufacturing facility in Shanghai in 2016, and obtained an EU QP’s declaration of GMP for conducting the clinical trials of its first four biosimilar products in Europe.